The molecular lab test was approved by the FDA in 2007 to detect breast cancer spreading to the lymph nodes. The test could be beneficial at the time of surgery to determine if additional lymph nodes should be removed instead of having a second surgical procedure. The clinical trials have also been halted. Their investments in cancer are still alive and well in other areas. BD
Pfizer Along With Johnson and Johnson Invest in Cancer Medical Device - Novo-Cure Stopping Growth of Tumor and Potential Reversal
Johnson & Johnson (JNJ) has voluntarily withdrawn a pioneering breast-cancer diagnostic test from the U.S. and European markets due to low usage.
J&J's Veridex unit withdrew the GeneSearch breast lymph-node assay- -which was designed to detect whether cancer had spread beyond the breasts--in late December, spokeswoman Devon Prutzman told Dow Jones Newswires on Monday.
"We were just finding that adoption of this as a tool to manage metastatic breast cancer has been relatively low," she said. Doctors appear to be satisfied with other methods of detection, such as "frozen section" assessment.
Prutzman declined to quantify usage or sales figures for GeneSearch.